The European Medicines Agency yesterday said it's launching an infringement procedure against...


The European Medicines Agency yesterday said it's launching an infringement procedure against Roche (RHHBY.OB) for not properly looking into 80,000 reports of issues received from U.S. patients and doctors relating to 19 of the company's drugs, including best-sellers Herceptin and Avastin. If found guilty of wrongdoing, Roche could face a fine of up to 5% of its annual revenues.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs